RYTM — Rhythm Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $6.06bn
- $5.83bn
- $189.76m
Rhythm's therapy becomes first FDA-approved treatment for brain damage-related obesity
Rhythm Pharma rises after FDA clears therapy for hypothalamic obesity
NASDAQ RESUMED AT 07:05 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:25 PM
U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson
Brief: Rhythm Pharmaceuticals Announces Topline Results From Phase 3 Emanate Trial
Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial (updated)
Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial
Brief: Rhythm Pharmaceuticals Says PDUFA Goal Date For Setmelanotide Is March 20, 2026
U.S. RESEARCH ROUNDUP-Cars.Com, Dell, Zscaler
Brief: Rhythm Pharmaceuticals Files For Mixed Shelf
Rhythm Q4 loss narrower than expected on higher IMCIVREE sales
Brief: Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter Results
U.S. STOCKS ON THE MOVE-Walt Disney, Titan Mining, Costco Wholesale
U.S. STOCKS ON THE MOVE-Nordson, Walt Disney, Titan Mining
U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond Hill
Rhythm Pharma rises on positive mid-stage data for rare disease therapy
Brief: Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome
U.S. STOCKS ON THE MOVE-Akamai Technologies, Enbridge, KKR